← Eichor
Study identifier: NCT07061678 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The Effect of Dexamethasone Administration Route in Pediatric Brachial Plexus Block

Condition: Arm  ·  Sponsor: Poznan University of Medical Sciences

PhasePhase 4
Planned participants90
Who can joinAll sexes, 3 Months to 6 Years
Healthy volunteersNo

About this study

This study aims to assess the impact of the administration route of dexamethasone (intravenous vs. perineural) on postoperative pain and inflammatory response in pediatric patients undergoing hip surgery. The primary outcome is postoperative pain intensity measured using an age-appropriate scale at multiple intervals. Secondary outcomes include inflammatory markers such as neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), opioid consumption, time-to-first rescue analgesia, and overall patient recovery. This randomized, double-blinded study seeks to improve pain management strategies and optimize anesthesia protocols in pediatric arm surgery.

This description comes directly from the study's public registry record.

Talk to the study team

Malgorzata Reysner, M.D. Ph.D.  ·  +48 61 873 83 03  ·  mreysner@ump.edu.pl

Always discuss trial participation with your own doctor first.

Locations (2)

Poznan University of Medical SciencesPoznan, PolandRecruiting
Poznan University of Medical SciencesPoznan, PolandNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07061678